APO Research
Talk to an analyst

APO RESEARCH · REPORT

VEGF Inhibitor Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global VEGF Inhibitor Drugs Market Outlook and Growth Opportunities 2026

2 January 2026190 pages

Choose your research edition.

Industry ResearchVEGF Inhibitor Drugs Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal VEGF Inhibitor Drugs Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal VEGF Inhibitor Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal VEGF Inhibitor Drugs Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal VEGF Inhibitor Drugs Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global VEGF Inhibitor Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for VEGF Inhibitor Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for VEGF Inhibitor Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for VEGF Inhibitor Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the VEGF Inhibitor Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the VEGF Inhibitor Drugs market include Sanofi, Novartis AG, Merck & Co., Inc., Eli Lilly & Company, Pfizer, GlaxoSmithKline plc, Bayer AG, Genentech, Inc. (Roche) and Bristol-Myers-Squibb Company, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global VEGF Inhibitor Drugs market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of VEGF Inhibitor Drugs and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents VEGF Inhibitor Drugs revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global VEGF Inhibitor Drugs market.

VEGF Inhibitor Drugs Segment by Company

Sanofi

Novartis AG

Merck & Co., Inc.

Eli Lilly & Company

Pfizer

GlaxoSmithKline plc

Bayer AG

Genentech, Inc. (Roche)

Bristol-Myers-Squibb Company

AstraZeneca plc

VEGF Inhibitor Drugs Segment by Type

Tyrosine Kinase Inhibitors

Monoclonal Antibodies

Others

VEGF Inhibitor Drugs Segment by Application

Oncology

Ophthalmology

Others

VEGF Inhibitor Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global VEGF Inhibitor Drugs status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the VEGF Inhibitor Drugs key companies, revenue, market share, and recent developments.

3. To split the VEGF Inhibitor Drugs breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions VEGF Inhibitor Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify VEGF Inhibitor Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze VEGF Inhibitor Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global VEGF Inhibitor Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of VEGF Inhibitor Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of VEGF Inhibitor Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global VEGF Inhibitor Drugs industry.

Chapter 3: Detailed analysis of VEGF Inhibitor Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of VEGF Inhibitor Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of VEGF Inhibitor Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. VEGF Inhibitor Drugs Industry Trends Table 2. VEGF Inhibitor Drugs Industry Drivers Table 3. VEGF Inhibitor Drugs Industry Opportunities and Challenges Table 4. VEGF Inhibitor Drugs Industry Restraints Table 5. Global VEGF Inhibitor Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global VEGF Inhibitor Drugs Revenue Share by Company (2021-2026) Table 7. Global VEGF Inhibitor Drugs Company Ranking, (2024-2026) & (US$ Million) Table 8. Global VEGF Inhibitor Drugs Key Company Manufacturing Base & Headquarters Table 9. Global VEGF Inhibitor Drugs Company, Product Type & Application Table 10. Global VEGF Inhibitor Drugs Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global VEGF Inhibitor Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Tyrosine Kinase Inhibitors Table 15. Significant Companies of Monoclonal Antibodies Table 16. Significant Companies of Others Table 17. Global VEGF Inhibitor Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global VEGF Inhibitor Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global VEGF Inhibitor Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global VEGF Inhibitor Drugs Sales Value Share by Type (2021-2026) Table 21. Global VEGF Inhibitor Drugs Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Oncology Table 23. Significant Companies of Ophthalmology Table 24. Significant Companies of Others Table 25. Global VEGF Inhibitor Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global VEGF Inhibitor Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global VEGF Inhibitor Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global VEGF Inhibitor Drugs Sales Value Share by Application (2021-2026) Table 29. Global VEGF Inhibitor Drugs Sales Value Share by Application (2027-2032) Table 30. Global VEGF Inhibitor Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global VEGF Inhibitor Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global VEGF Inhibitor Drugs Sales Value Share by Region (2021-2026) Table 33. Global VEGF Inhibitor Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global VEGF Inhibitor Drugs Sales Value Share by Region (2027-2032) Table 35. Global VEGF Inhibitor Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global VEGF Inhibitor Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global VEGF Inhibitor Drugs Sales Value Market Share by Country (2021-2026) Table 38. Global VEGF Inhibitor Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global VEGF Inhibitor Drugs Sales Value Market Share by Country (2027-2032) Table 40. Sanofi Company Information Table 41. Sanofi Business Overview Table 42. Sanofi VEGF Inhibitor Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Sanofi VEGF Inhibitor Drugs Product Portfolio Table 44. Sanofi Recent Development Table 45. Novartis AG Company Information Table 46. Novartis AG Business Overview Table 47. Novartis AG VEGF Inhibitor Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Novartis AG VEGF Inhibitor Drugs Product Portfolio Table 49. Novartis AG Recent Development Table 50. Merck & Co., Inc. Company Information Table 51. Merck & Co., Inc. Business Overview Table 52. Merck & Co., Inc. VEGF Inhibitor Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Merck & Co., Inc. VEGF Inhibitor Drugs Product Portfolio Table 54. Merck & Co., Inc. Recent Development Table 55. Eli Lilly & Company Company Information Table 56. Eli Lilly & Company Business Overview Table 57. Eli Lilly & Company VEGF Inhibitor Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Eli Lilly & Company VEGF Inhibitor Drugs Product Portfolio Table 59. Eli Lilly & Company Recent Development Table 60. Pfizer Company Information Table 61. Pfizer Business Overview Table 62. Pfizer VEGF Inhibitor Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Pfizer VEGF Inhibitor Drugs Product Portfolio Table 64. Pfizer Recent Development Table 65. GlaxoSmithKline plc Company Information Table 66. GlaxoSmithKline plc Business Overview Table 67. GlaxoSmithKline plc VEGF Inhibitor Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. GlaxoSmithKline plc VEGF Inhibitor Drugs Product Portfolio Table 69. GlaxoSmithKline plc Recent Development Table 70. Bayer AG Company Information Table 71. Bayer AG Business Overview Table 72. Bayer AG VEGF Inhibitor Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Bayer AG VEGF Inhibitor Drugs Product Portfolio Table 74. Bayer AG Recent Development Table 75. Genentech, Inc. (Roche) Company Information Table 76. Genentech, Inc. (Roche) Business Overview Table 77. Genentech, Inc. (Roche) VEGF Inhibitor Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Genentech, Inc. (Roche) VEGF Inhibitor Drugs Product Portfolio Table 79. Genentech, Inc. (Roche) Recent Development Table 80. Bristol-Myers-Squibb Company Company Information Table 81. Bristol-Myers-Squibb Company Business Overview Table 82. Bristol-Myers-Squibb Company VEGF Inhibitor Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Bristol-Myers-Squibb Company VEGF Inhibitor Drugs Product Portfolio Table 84. Bristol-Myers-Squibb Company Recent Development Table 85. AstraZeneca plc Company Information Table 86. AstraZeneca plc Business Overview Table 87. AstraZeneca plc VEGF Inhibitor Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. AstraZeneca plc VEGF Inhibitor Drugs Product Portfolio Table 89. AstraZeneca plc Recent Development Table 90. Research Programs/Design for This Report Table 91. Authors List of This Report Table 92. Secondary Sources Table 93. Primary Sources List of Figures Figure 1. VEGF Inhibitor Drugs Product Image Figure 2. Global VEGF Inhibitor Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global VEGF Inhibitor Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global VEGF Inhibitor Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Tyrosine Kinase Inhibitors Image Figure 8. Monoclonal Antibodies Image Figure 9. Others Image Figure 10. Global VEGF Inhibitor Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global VEGF Inhibitor Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global VEGF Inhibitor Drugs Sales Value Share by Type (2021-2032) Figure 13. Oncology Image Figure 14. Ophthalmology Image Figure 15. Others Image Figure 16. Global VEGF Inhibitor Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global VEGF Inhibitor Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global VEGF Inhibitor Drugs Sales Value Share by Application (2021-2032) Figure 19. Global VEGF Inhibitor Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global VEGF Inhibitor Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America VEGF Inhibitor Drugs Sales Value (2021-2032) & (US$ Million) Figure 22. North America VEGF Inhibitor Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe VEGF Inhibitor Drugs Sales Value (2021-2032) & (US$ Million) Figure 24. Europe VEGF Inhibitor Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific VEGF Inhibitor Drugs Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific VEGF Inhibitor Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America VEGF Inhibitor Drugs Sales Value (2021-2032) & (US$ Million) Figure 28. South America VEGF Inhibitor Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa VEGF Inhibitor Drugs Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa VEGF Inhibitor Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA VEGF Inhibitor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA VEGF Inhibitor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA VEGF Inhibitor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada VEGF Inhibitor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada VEGF Inhibitor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada VEGF Inhibitor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico VEGF Inhibitor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico VEGF Inhibitor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico VEGF Inhibitor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany VEGF Inhibitor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany VEGF Inhibitor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany VEGF Inhibitor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France VEGF Inhibitor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France VEGF Inhibitor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France VEGF Inhibitor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. VEGF Inhibitor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. VEGF Inhibitor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. VEGF Inhibitor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy VEGF Inhibitor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy VEGF Inhibitor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy VEGF Inhibitor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain VEGF Inhibitor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain VEGF Inhibitor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain VEGF Inhibitor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia VEGF Inhibitor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia VEGF Inhibitor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia VEGF Inhibitor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands VEGF Inhibitor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands VEGF Inhibitor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands VEGF Inhibitor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries VEGF Inhibitor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries VEGF Inhibitor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries VEGF Inhibitor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China VEGF Inhibitor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China VEGF Inhibitor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China VEGF Inhibitor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan VEGF Inhibitor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan VEGF Inhibitor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan VEGF Inhibitor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea VEGF Inhibitor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea VEGF Inhibitor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea VEGF Inhibitor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India VEGF Inhibitor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India VEGF Inhibitor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India VEGF Inhibitor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia VEGF Inhibitor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia VEGF Inhibitor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia VEGF Inhibitor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia VEGF Inhibitor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia VEGF Inhibitor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia VEGF Inhibitor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil VEGF Inhibitor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil VEGF Inhibitor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil VEGF Inhibitor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina VEGF Inhibitor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina VEGF Inhibitor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina VEGF Inhibitor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile VEGF Inhibitor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile VEGF Inhibitor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile VEGF Inhibitor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia VEGF Inhibitor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia VEGF Inhibitor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia VEGF Inhibitor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru VEGF Inhibitor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru VEGF Inhibitor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru VEGF Inhibitor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia VEGF Inhibitor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia VEGF Inhibitor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia VEGF Inhibitor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel VEGF Inhibitor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel VEGF Inhibitor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel VEGF Inhibitor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE VEGF Inhibitor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE VEGF Inhibitor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE VEGF Inhibitor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey VEGF Inhibitor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey VEGF Inhibitor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey VEGF Inhibitor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran VEGF Inhibitor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran VEGF Inhibitor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran VEGF Inhibitor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt VEGF Inhibitor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt VEGF Inhibitor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt VEGF Inhibitor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Tyrosine Kinase Inhibitors
  • Monoclonal Antibodies
  • Others
Applications
  • Oncology
  • Ophthalmology
  • Others
Companies covered
  • Sanofi
  • Novartis AG
  • Merck & Co., Inc.
  • Eli Lilly & Company
  • Pfizer
  • GlaxoSmithKline plc
  • Bayer AG
  • Genentech, Inc. (Roche)
  • Bristol-Myers-Squibb Company
  • AstraZeneca plc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global VEGF Inhibitor Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global VEGF Inhibitor Drugs Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 VEGF Inhibitor Drugs Market Dynamics
  1. 2.1 VEGF Inhibitor Drugs Industry Trends
  2. 2.2 VEGF Inhibitor Drugs Industry Drivers
  3. 2.3 VEGF Inhibitor Drugs Industry Opportunities and Challenges
  4. 2.4 VEGF Inhibitor Drugs Industry Restraints
3 VEGF Inhibitor Drugs Market by Company
  1. 3.1 Global VEGF Inhibitor Drugs Company Revenue Ranking in 2025
  2. 3.2 Global VEGF Inhibitor Drugs Revenue by Company (2021-2026)
  3. 3.3 Global VEGF Inhibitor Drugs Company Ranking (2024-2026)
  4. 3.4 Global VEGF Inhibitor Drugs Company Manufacturing Base and Headquarters
  5. 3.5 Global VEGF Inhibitor Drugs Company Product Type and Application
  6. 3.6 Global VEGF Inhibitor Drugs Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global VEGF Inhibitor Drugs Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 VEGF Inhibitor Drugs Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 VEGF Inhibitor Drugs Market by Type
  1. 4.1 VEGF Inhibitor Drugs Type Introduction
  2. 4.1.1 Tyrosine Kinase Inhibitors
  3. 4.1.2 Monoclonal Antibodies
  4. 4.1.3 Others
  5. 4.2 Global VEGF Inhibitor Drugs Sales Value by Type
  6. 4.2.1 Global VEGF Inhibitor Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global VEGF Inhibitor Drugs Sales Value by Type (2021-2032)
  8. 4.2.3 Global VEGF Inhibitor Drugs Sales Value Share by Type (2021-2032)
5 VEGF Inhibitor Drugs Market by Application
  1. 5.1 VEGF Inhibitor Drugs Application Introduction
  2. 5.1.1 Oncology
  3. 5.1.2 Ophthalmology
  4. 5.1.3 Others
  5. 5.2 Global VEGF Inhibitor Drugs Sales Value by Application
  6. 5.2.1 Global VEGF Inhibitor Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global VEGF Inhibitor Drugs Sales Value by Application (2021-2032)
  8. 5.2.3 Global VEGF Inhibitor Drugs Sales Value Share by Application (2021-2032)
6 VEGF Inhibitor Drugs Regional Value Analysis
  1. 6.1 Global VEGF Inhibitor Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global VEGF Inhibitor Drugs Sales Value by Region (2021-2032)
  3. 6.2.1 Global VEGF Inhibitor Drugs Sales Value by Region: 2021-2026
  4. 6.2.2 Global VEGF Inhibitor Drugs Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America VEGF Inhibitor Drugs Sales Value (2021-2032)
  7. 6.3.2 North America VEGF Inhibitor Drugs Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe VEGF Inhibitor Drugs Sales Value (2021-2032)
  10. 6.4.2 Europe VEGF Inhibitor Drugs Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific VEGF Inhibitor Drugs Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific VEGF Inhibitor Drugs Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America VEGF Inhibitor Drugs Sales Value (2021-2032)
  16. 6.6.2 South America VEGF Inhibitor Drugs Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa VEGF Inhibitor Drugs Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa VEGF Inhibitor Drugs Sales Value Share by Country, 2025 VS 2032
7 VEGF Inhibitor Drugs Country-level Value Analysis
  1. 7.1 Global VEGF Inhibitor Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global VEGF Inhibitor Drugs Sales Value by Country (2021-2032)
  3. 7.2.1 Global VEGF Inhibitor Drugs Sales Value by Country (2021-2026)
  4. 7.2.2 Global VEGF Inhibitor Drugs Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA VEGF Inhibitor Drugs Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA VEGF Inhibitor Drugs Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA VEGF Inhibitor Drugs Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada VEGF Inhibitor Drugs Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada VEGF Inhibitor Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada VEGF Inhibitor Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico VEGF Inhibitor Drugs Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico VEGF Inhibitor Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico VEGF Inhibitor Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany VEGF Inhibitor Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany VEGF Inhibitor Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany VEGF Inhibitor Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France VEGF Inhibitor Drugs Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France VEGF Inhibitor Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France VEGF Inhibitor Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. VEGF Inhibitor Drugs Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. VEGF Inhibitor Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. VEGF Inhibitor Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy VEGF Inhibitor Drugs Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy VEGF Inhibitor Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy VEGF Inhibitor Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain VEGF Inhibitor Drugs Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain VEGF Inhibitor Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain VEGF Inhibitor Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia VEGF Inhibitor Drugs Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia VEGF Inhibitor Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia VEGF Inhibitor Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands VEGF Inhibitor Drugs Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands VEGF Inhibitor Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands VEGF Inhibitor Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries VEGF Inhibitor Drugs Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries VEGF Inhibitor Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries VEGF Inhibitor Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China VEGF Inhibitor Drugs Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China VEGF Inhibitor Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China VEGF Inhibitor Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan VEGF Inhibitor Drugs Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan VEGF Inhibitor Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan VEGF Inhibitor Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea VEGF Inhibitor Drugs Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea VEGF Inhibitor Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea VEGF Inhibitor Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India VEGF Inhibitor Drugs Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India VEGF Inhibitor Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India VEGF Inhibitor Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia VEGF Inhibitor Drugs Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia VEGF Inhibitor Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia VEGF Inhibitor Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia VEGF Inhibitor Drugs Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia VEGF Inhibitor Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia VEGF Inhibitor Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil VEGF Inhibitor Drugs Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil VEGF Inhibitor Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil VEGF Inhibitor Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina VEGF Inhibitor Drugs Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina VEGF Inhibitor Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina VEGF Inhibitor Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile VEGF Inhibitor Drugs Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile VEGF Inhibitor Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile VEGF Inhibitor Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia VEGF Inhibitor Drugs Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia VEGF Inhibitor Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia VEGF Inhibitor Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru VEGF Inhibitor Drugs Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru VEGF Inhibitor Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru VEGF Inhibitor Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia VEGF Inhibitor Drugs Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia VEGF Inhibitor Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia VEGF Inhibitor Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel VEGF Inhibitor Drugs Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel VEGF Inhibitor Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel VEGF Inhibitor Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE VEGF Inhibitor Drugs Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE VEGF Inhibitor Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE VEGF Inhibitor Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey VEGF Inhibitor Drugs Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey VEGF Inhibitor Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey VEGF Inhibitor Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran VEGF Inhibitor Drugs Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran VEGF Inhibitor Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran VEGF Inhibitor Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt VEGF Inhibitor Drugs Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt VEGF Inhibitor Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt VEGF Inhibitor Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi
  2. 8.1.1 Sanofi Company Information
  3. 8.1.2 Sanofi Business Overview
  4. 8.1.3 Sanofi VEGF Inhibitor Drugs Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi VEGF Inhibitor Drugs Product Portfolio
  6. 8.1.5 Sanofi Recent Developments
  7. 8.2 Novartis AG
  8. 8.2.1 Novartis AG Company Information
  9. 8.2.2 Novartis AG Business Overview
  10. 8.2.3 Novartis AG VEGF Inhibitor Drugs Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Novartis AG VEGF Inhibitor Drugs Product Portfolio
  12. 8.2.5 Novartis AG Recent Developments
  13. 8.3 Merck & Co., Inc.
  14. 8.3.1 Merck & Co., Inc. Company Information
  15. 8.3.2 Merck & Co., Inc. Business Overview
  16. 8.3.3 Merck & Co., Inc. VEGF Inhibitor Drugs Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Merck & Co., Inc. VEGF Inhibitor Drugs Product Portfolio
  18. 8.3.5 Merck & Co., Inc. Recent Developments
  19. 8.4 Eli Lilly & Company
  20. 8.4.1 Eli Lilly & Company Company Information
  21. 8.4.2 Eli Lilly & Company Business Overview
  22. 8.4.3 Eli Lilly & Company VEGF Inhibitor Drugs Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Eli Lilly & Company VEGF Inhibitor Drugs Product Portfolio
  24. 8.4.5 Eli Lilly & Company Recent Developments
  25. 8.5 Pfizer
  26. 8.5.1 Pfizer Company Information
  27. 8.5.2 Pfizer Business Overview
  28. 8.5.3 Pfizer VEGF Inhibitor Drugs Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Pfizer VEGF Inhibitor Drugs Product Portfolio
  30. 8.5.5 Pfizer Recent Developments
  31. 8.6 GlaxoSmithKline plc
  32. 8.6.1 GlaxoSmithKline plc Company Information
  33. 8.6.2 GlaxoSmithKline plc Business Overview
  34. 8.6.3 GlaxoSmithKline plc VEGF Inhibitor Drugs Revenue and Gross Margin (2021-2026)
  35. 8.6.4 GlaxoSmithKline plc VEGF Inhibitor Drugs Product Portfolio
  36. 8.6.5 GlaxoSmithKline plc Recent Developments
  37. 8.7 Bayer AG
  38. 8.7.1 Bayer AG Company Information
  39. 8.7.2 Bayer AG Business Overview
  40. 8.7.3 Bayer AG VEGF Inhibitor Drugs Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Bayer AG VEGF Inhibitor Drugs Product Portfolio
  42. 8.7.5 Bayer AG Recent Developments
  43. 8.8 Genentech, Inc. (Roche)
  44. 8.8.1 Genentech, Inc. (Roche) Company Information
  45. 8.8.2 Genentech, Inc. (Roche) Business Overview
  46. 8.8.3 Genentech, Inc. (Roche) VEGF Inhibitor Drugs Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Genentech, Inc. (Roche) VEGF Inhibitor Drugs Product Portfolio
  48. 8.8.5 Genentech, Inc. (Roche) Recent Developments
  49. 8.9 Bristol-Myers-Squibb Company
  50. 8.9.1 Bristol-Myers-Squibb Company Company Information
  51. 8.9.2 Bristol-Myers-Squibb Company Business Overview
  52. 8.9.3 Bristol-Myers-Squibb Company VEGF Inhibitor Drugs Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Bristol-Myers-Squibb Company VEGF Inhibitor Drugs Product Portfolio
  54. 8.9.5 Bristol-Myers-Squibb Company Recent Developments
  55. 8.10 AstraZeneca plc
  56. 8.10.1 AstraZeneca plc Company Information
  57. 8.10.2 AstraZeneca plc Business Overview
  58. 8.10.3 AstraZeneca plc VEGF Inhibitor Drugs Revenue and Gross Margin (2021-2026)
  59. 8.10.4 AstraZeneca plc VEGF Inhibitor Drugs Product Portfolio
  60. 8.10.5 AstraZeneca plc Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst